Investors
November 20, 2025
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…
September 25, 2025
– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …
July 1, 2025
Q1 FY 26 HIGHLIGHTS – Maxigesic IV® (marketed as Combogesic IV®) launching in Canada this month and sales kick off for AFT Pharmaceuticals Canada a…